PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies. The company is also involved in manufacturing peptides for commercially approved peptide therapeutics. In addition, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. Further, the company offers regulatory affair support services. The company was founded in 1952 and is headquartered in Zug, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
P/S ratio for PolyPeptide Group AG (PPGN.SW)
P/S ratio as of 2023: 1.94
According to PolyPeptide Group AG's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.94. At the end of 2022 the company had a P/S ratio of 3.00.
P/S ratio history for PolyPeptide Group AG from 2018 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 1.94 |
| 2022 | 3.00 |
| 2021 | 15.02 |
| 2020 | 7.73 |
| 2019 | 8.52 |
| 2018 | 9.28 |